367 related articles for article (PubMed ID: 29318974)
1. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities.
Merelli A; RodrÃguez JCG; Folch J; Regueiro MR; Camins A; Lazarowski A
Curr Neuropharmacol; 2018; 16(10):1484-1498. PubMed ID: 29318974
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy.
Merelli A; Czornyj L; Lazarowski A
Curr Pharm Des; 2013; 19(38):6791-801. PubMed ID: 23530506
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain.
Kupershmidt L; Weinreb O; Amit T; Mandel S; Bar-Am O; Youdim MB
Neuroscience; 2011 Aug; 189():345-58. PubMed ID: 21570450
[TBL] [Abstract][Full Text] [Related]
6. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia inducible factor-1 as a target for neurodegenerative diseases.
Zhang Z; Yan J; Chang Y; ShiDu Yan S; Shi H
Curr Med Chem; 2011; 18(28):4335-43. PubMed ID: 21861815
[TBL] [Abstract][Full Text] [Related]
8. Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice.
Xu SF; Zhang YH; Wang S; Pang ZQ; Fan YG; Li JY; Wang ZY; Guo C
Redox Biol; 2019 Feb; 21():101090. PubMed ID: 30593976
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia, Oxidative Stress, and Inflammation: Three Faces of Neurodegenerative Diseases.
Merelli A; Repetto M; Lazarowski A; Auzmendi J
J Alzheimers Dis; 2021; 82(s1):S109-S126. PubMed ID: 33325385
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor 1alpha (HIF-1alpha) is a non-heme iron protein. Implications for oxygen sensing.
Srinivas V; Zhu X; Salceda S; Nakamura R; Caro J
J Biol Chem; 1998 Jul; 273(29):18019-22. PubMed ID: 9660756
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.
Siddiq A; Aminova LR; Troy CM; Suh K; Messer Z; Semenza GL; Ratan RR
J Neurosci; 2009 Jul; 29(27):8828-38. PubMed ID: 19587290
[TBL] [Abstract][Full Text] [Related]
12. Role of HIF-1 in iron regulation: potential therapeutic strategy for neurodegenerative disorders.
Lee DW; Andersen JK
Curr Mol Med; 2006 Dec; 6(8):883-93. PubMed ID: 17168739
[TBL] [Abstract][Full Text] [Related]
13. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
15. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
16. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.
Mandel S; Amit T; Reznichenko L; Weinreb O; Youdim MB
Mol Nutr Food Res; 2006 Feb; 50(2):229-34. PubMed ID: 16470637
[TBL] [Abstract][Full Text] [Related]
17. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
Merelli A; Caltana L; Lazarowski A; Brusco A
Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
[TBL] [Abstract][Full Text] [Related]
18. The role of iron in brain ageing and neurodegenerative disorders.
Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
Kupershmidt L; Weinreb O; Amit T; Mandel S; Carri MT; Youdim MB
FASEB J; 2009 Nov; 23(11):3766-79. PubMed ID: 19638399
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia and the HIF system in kidney disease.
Nangaku M; Eckardt KU
J Mol Med (Berl); 2007 Dec; 85(12):1325-30. PubMed ID: 18026918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
